Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2022 wishlist
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Hypertension
    • Patents and intellectual property
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2022 wishlist
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19
      • Explainer: A bold proposal at the WTO by India and South Africa
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Hypertension
    • Patents and intellectual property
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
      • Explainer: COVID-19 vaccines - Recommendations for equitable access
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • No Patents in a Pandemic
      • 20 years of Advocacy in Action
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Spotlight pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!
Get involved
Our campaigns
""
Newsletter

The Access Campaign Newsletters

""

Read, watch, share

Share the Tech - Save Lives
Newsletter
Newsletter |
10 September 2021
COVID-19

Share the Tech – Save Lives

No Patents Council Map 18 January 2022
Newsletter
Newsletter |
26 July 2021
COVID-19

Twitter storm! Tell Germany, UK and Norway to stop blocking the COVID-19 monopoly waiver!

Newsletter cover image
Newsletter
Newsletter |
23 July 2021
COVID-19

#NoCovidMonopolies. Thank you for helping us shape history!

In Portel, MSF teams developed activities in the rural areas where people struggle to access basic medical care. During the longest mobile clinic, through the Anapu river, activities lasted 8 days and our teams visited 4 communities. MSF treated 390 patients.
Newsletter
Newsletter |
22 June 2021
COVID-19

Share vaccine knowledge to save lives!

Pharma guidelines dictate that most forms of insulin must be stored in a fridge, and once opened, kept below 25°C. But MSF research shows that insulin can be stored in temperatures that reach up to 37°C and remain effective. These findings will make a huge difference to the lives of people in places like Dadaab refugee camp, Kenya, where temperatures can rocket, and not everyone has home access to a refrigerator.
Newsletter
Newsletter |
25 May 2021
COVID-19

100 years since insulin was discovered: why are people still waiting for treatment?

""
Newsletter
Newsletter |
03 May 2021
COVID-19

BREAKING: Join our high-level event on the WTO IP waiver

Quote comes from MSF AC Press Release from 21st April 2021, "After encouraging statement from US on landmark COVID-19 monopoly waiver, MSF calls on all opposing countries to relent ahead of next talks"
Newsletter
Newsletter |
22 April 2021
COVID-19

TODAY: A chance to stop COVID-19 Monopolies

In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich.
Newsletter
Newsletter |
24 March 2021
COVID-19

World TB Day - FB Live: A journey with a TB survivor

  • Load More
Navigate
  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access Campaign
Médecins Sans Frontières
Route de Ferney 140 
P.O. Box 1224
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us
  • Twitter
  • Facebook
  • Vimeo
  • Medium
Medicines Shouldn't Be A Luxury